[Safety and tolerance]Percentage of subjects who reported any adverse event even onceFrequency of each adverse event item after codingPercentage of subjects who reported the relevant adverse event even once by gradeSummary statistics for safety-related inspection items[Immunogenicity] Geometric mean of neutralizing antibody titers of each group against SARS-CoV-2 at four weeks after the investigational drug; and geometric mean fold rise of neutralizing antibody titers of each group against SARS-CoV-2 after the investigational drug compared to the titer before the first vaccination

[Safety and tolerance]Percentage of subjects who reported any adverse event even onceFrequency of each adverse event item after codingPercentage of subjects who reported the relevant adverse event even once by gradeSummary statistics for safety-related inspection items[Immunogenicity] Geometric mean of neutralizing antibody titers of each group against SARS-CoV-2 at four weeks after the investigational drug; and geometric mean fold rise of neutralizing antibody titers of each group against SARS-CoV-2 after the investigational drug compared to the titer before the first vaccination